Detection of significant antiviral drug effects on COVID-19 with reasonable sample sizes in randomized controlled trials: A modeling study

Development of an effective antiviral drug for Coronavirus Disease 2019 (COVID-19) is a global health priority. Although several candidate drugs have been identified through in vitro and in vivo models, consistent and compelling evidence from clinical studies is limited. The lack of evidence from cl...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	PLoS medicine 2021-07, Vol.18 (7), p.e1003660-e1003660
Hauptverfasser:	Iwanami, Shoya, Ejima, Keisuke, Kim, Kwang Su, Noshita, Koji, Fujita, Yasuhisa, Miyazaki, Taiga, Kohno, Shigeru, Miyazaki, Yoshitsugu, Morimoto, Shimpei, Nakaoka, Shinji, Koizumi, Yoshiki, Asai, Yusuke, Aihara, Kazuyuki, Watashi, Koichi, Thompson, Robin N, Shibuya, Kenji, Fujiu, Katsuhito, Perelson, Alan S, Iwami, Shingo, Wakita, Takaji
Format:	Artikel
Sprache:	eng
Schlagworte:	60 APPLIED LIFE SCIENCES Analysis Antiviral agents Antiviral drugs Antiviral therapy Antivirals Biological Science Biology and Life Sciences Clinical outcomes Clinical trials Coronaviruses COVID-19 Drug development Drugs Experimental design Mathematical models Medicine and Health Sciences Methods Parameter estimation Patients Placebos Public health Randomized controlled trials Research and Analysis Methods SARS CoV 2 Severe acute respiratory syndrome coronavirus 2 Statistical analysis Testing Viral load Viral replication Viruses
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!